Bristol Myers reports two Phase 3 successes for fibrosis and RayzeBio drug

Bristol Myers Squibb announced Monday that two of its late-stage trials have met primary endpoints.

The first trial involved its fibrosis program, where the experimental therapy demonstrated the expected benefit in patients with the disease.

The second success came from a RayzeBio-partnered drug that had previously faced safety concerns; the Phase 3 data showed it achieved its efficacy goals without new safety signals.